Ricilina

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ricilina

Understanding Ricilina

Ricilina is a pharmacological agent primarily categorized as an antineoplastic or cytotoxic medication. It is utilized in specialized medical settings for the treatment of specific types of malignancies. As a therapeutic tool, it belongs to a class of compounds designed to interfere with the cellular processes that allow abnormal cells to proliferate.

Mechanism of Action

The primary function of Ricilina involves the inhibition of protein synthesis within target cells. At a molecular level, the active components of the medication interact with the ribosomes—the machinery responsible for translating genetic information into functional proteins. By disrupting this translation process, Ricilina effectively prevents the cell from maintaining its structure and replicating its genetic material, eventually leading to programmed cell death.

Therapeutic Application

In clinical practice, Ricilina is typically reserved for cases where standard therapies may need to be supplemented or where specific cellular markers are present. Its use is focused on targeting rapidly dividing cells, which is a hallmark of many oncological conditions. Because it acts on fundamental biological pathways, its application is carefully monitored to ensure it addresses the underlying pathology of the condition being treated.

Chemical Composition and Origin

Ricilina is derived from specific glycoproteins. These complex molecules are structured to recognize and bind to certain receptors on the surface of cells. Once bound, the molecule is internalized, allowing it to exert its inhibitory effects from within the cell body. This targeted approach is a key characteristic of its design, aiming to focus the therapeutic impact on the intended cellular environment.

Regulatory References

  1. Azithromycin Drug Information (NIH)

What side effects are possible with Ricilina?

Ricilina, which contains the active ingredient Azithromycin, has an official safety profile categorized by adverse reactions based on their frequency and the body system affected, according to regulatory documents from health authorities like the FDA and EMA.

Adverse Reaction Classifications

The most frequently documented events, classified as Common in regulatory labeling, are typically gastrointestinal disorders. These include effects such as diarrhea or loose stools, nausea, abdominal pain, and vomiting. Less common effects, listed as Uncommon or Rare, involve other systems, such as the nervous system (dizziness, headache) and skin (rash, photosensitivity).

Serious Safety Considerations

The official label explicitly details potentially serious adverse reactions. These include severe liver injury, such as hepatic failure and cholestatic jaundice, which are uncommon but critical. The safety profile also emphasizes the risk of serious cardiac disorders, specifically QT interval prolongation and the life-threatening arrhythmia Torsades de pointes.

Regulatory documents also list severe allergic reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as the potential for Clostridioides difficile-Associated Diarrhea (CDAD).

Population and Timing Notes

The official prescribing information includes specific safety constraints for certain patient groups. For example, the medication is generally restricted for use in patients with a prior history of hepatic dysfunction associated with Azithromycin use, and caution is noted for those with severe renal impairment. Furthermore, official regulatory statements note that the potential for increased cardiovascular risk is greatest during the first five days of treatment, establishing a time-related safety pattern for close observation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Ricilina (Azithromycin) details specific manifestations and actions required in the event of overdosage. Overdose presentations are characterized by an amplification of known effects, predominantly involving the gastrointestinal system. Symptoms commonly described include severe nausea, vomiting, diarrhea, and stomach discomfort. Overexposure to macrolide antibiotics has also been associated with potential reversible loss of hearing.

A more serious concern documented by regulators is the risk of cardiac electrical instability. Overdose may be linked to prolongation of the QT interval, which increases the danger of developing a fatal cardiac arrhythmia, specifically Torsades de pointes. Due to this documented life-threatening risk, official instructions mandate that immediate medical attention must be sought if cardiac symptoms such as irregular heartbeat, dizziness, fainting, or shortness of breath occur.

In the case of an overdose, management is limited to general symptomatic and supportive measures as no specific antidote is available or described in the official protocols. Monitoring, such as an ECG screening, is considered for high-risk individuals, particularly the elderly and women, who are noted as being more susceptible to the severe cardiac risks.

Therapeutic Uses of Ricilina

What Ricilina Treats: Main Uses and Benefits

Ricilina (Azithromycin) is used to combat systemic bacterial infections, generally providing supportive relief to ease the symptomatic burden across several key clinical domains. This medication is applied in conditions presenting with systemic or localized discomfort across several systems.

Therapeutic Scope and Symptom Management

Ricilina is relevant for managing acute bacterial conditions characterized by periods of heightened symptoms. This includes infections of the respiratory tract (like Community-Acquired Pneumonia and pharyngitis), skin and soft tissues, the middle ear (otitis media), and certain sexually transmitted infections (STIs). It is commonly used to help address symptom clusters that interfere with daily comfort, such as fever, persistent cough, pain, swelling, and localized tenderness.

It is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that may help patients cope more steadily with difficult manifestations. The medication provides support that helps ease the overall symptom burden during episodes of heightened discomfort. By addressing the infectious source, it contributes to supporting general well-being and functional stability. The medication is also commonly used in patient groups, such as those with a known penicillin allergy, for managing streptococcal infections.


Quick Fact Block

Quick Fact: Relief for Respiratory Discomfort
Ricilina is commonly used to help manage cough, shortness of breath, and sore throat symptoms when they are associated with an underlying bacterial infection.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ricilina?

The eligibility to use Ricilina (Azithromycin) is determined by official regulatory criteria focusing on absolute contraindications, pre-existing conditions, and age limits.


Eligibility Scope

Category Official Regulatory Status
Contraindications MUST NOT USE if there is a known hypersensitivity to Azithromycin, Erythromycin, or any macrolide antibiotic, or a history of Azithromycin-associated cholestatic jaundice.
Age Limits NOT ESTABLISHED for infants under six months of age for most approved uses. Caution is advised for infants under 42 days of life due to reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Restrictions USE WITH CAUTION is required for patients with severe renal impairment or severe liver disease.
Comorbidities USE WITH CAUTION in patients with myasthenia gravis, known QT interval prolongation, or uncompensated heart failure.
Pregnancy/Lactation USE ONLY IF CLEARLY NEEDED during pregnancy. NOT RECOMMENDED for breastfeeding mothers, requiring a decision to discontinue the drug or nursing.

Connection to the Eligibility Profile

Regulatory bodies establish eligibility by prohibiting Ricilina use based on absolute risks, such as prior macrolide allergy or liver damage. Use is restricted by patient physiology, requiring caution in those with severe organ impairment or cardiac risk factors. These rules mandate limited use in vulnerable groups like infants and pregnant individuals where safety data may be incomplete or risks are elevated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ricilina may interact with a number of other medicines, herbal products, and certain non-medicinal substances, which can alter the drug's effects, the effects of the other product, or increase the risk of adverse events. It is essential to discuss all current and planned medications with a healthcare professional before starting Ricilina.

Interactions often occur through changes in how the body processes the medication, such as effects on drug-metabolizing enzymes (like CYP3A4) or transport proteins (like P-glycoprotein). These mechanisms can result in higher or lower levels of either Ricilina or the co-administered drug in the bloodstream.

Key Interacting Medicinal Product Categories:

Category Examples of Affected Drugs Clinical Concern
Anticoagulants Warfarin Increased risk of bleeding; close monitoring of blood coagulation is necessary.
Cardiovascular Agents Drugs that prolong the QT interval (e.g., Amiodarone, Sotalol) Increased risk of serious heart rhythm abnormalities.
Immunosuppressants Cyclosporine, Tacrolimus Increased levels of the immunosuppressant; requires careful drug level monitoring.
Gout Medications Colchicine Increased risk of colchicine toxicity, potentially leading to severe complications.
HIV/AIDS Medications Nelfinavir Altered blood levels of both Ricilina and the HIV medication; warrants close monitoring.

Food/Beverage Interactions:

Specific interactions with grapefruit juice have been noted for some related medications, leading to increased drug exposure. It is generally advisable to seek specific guidance regarding the consumption of grapefruit and its juice while taking Ricilina.

To ensure safe use, a comprehensive review of all prescription and non-prescription products is required, including vitamins and herbal supplements.

Mechanism of Action

The action of Ricilina (Azithromycin) involves a dual mechanism focused on arresting bacterial proliferation and modulating the host's inflammatory state. This effect is sustained by the drug's unique distribution pattern which targets the site of biological stress.

Targeted Blockade of Bacterial Protein Synthesis

Ricilina's core mechanism is its function as a protein synthesis inhibitor within susceptible bacteria. The molecule binds with high affinity to the 50S ribosomal subunit, specifically interfering with the 23S rRNA, which physically blocks the growth of new peptide chains. This action instantly halts microbial growth and replication (bacteriostasis), thereby lowering the infectious burden and permitting subsequent clearance of the non-replicating pathogens by host immune cells.

Modulating Host Immune and Tissue Response

Independent of its direct antimicrobial action, Azithromycin also acts as an immunomodulator, targeting the host's immune system. The drug accumulates within immune cells like macrophages and neutrophils and regulates key inflammatory mediator pathways by reducing the output of pro-inflammatory cytokines. This activity limits excessive immune signaling and tissue influx, which contributes to modulating local hyper-inflammatory signaling and influencing pathways that lead to altered physiological response.

Dosage and Administration Information

How to Use Ricilina (Azithromycin)

Ricilina administration is defined by specific protocols, specifying fixed-duration courses and distinct routes for systemic delivery. The medication is primarily available for oral intake as tablets, capsules, or suspensions, and in a powdered form for intravenous (IV) infusion.

Dosing and Duration

Adult dosing regimens typically follow a short-course model, often prescribed as 500 mg once daily for 3 days, or alternatively, a 5-day course starting with 500 mg on the first day followed by 250 mg daily for the subsequent four days. For certain specific infections, a single dose of 1000 mg is utilized. For serious initial therapy, 500 mg IV once daily is administered, which must transition to the oral form to complete the total treatment course.

Administration Contexts

Standard oral forms of Ricilina may be taken with or without food. A key exception is the extended-release oral suspension, which is instructed to be taken on an empty stomach (at least one hour before or two hours after a meal). Pediatric dosing is not fixed but is calculated based on body weight (e.g., 10 or 12 mg/kg) to ensure the correct amount is delivered via the oral suspension.

Procedural Requirements

When the IV route is used, the powdered form requires both reconstitution and subsequent dilution into an approved intravenous solution. The final diluted solution must be administered as a slow intravenous infusion over a period of 60 minutes or longer; instructions explicitly forbid administration as a quick bolus or intramuscular injection.

Recent Clinical Evidence

Research Evidence for Ricilina: Overview of Studies

Evidence for Use in Acute Respiratory and Skin Infections

Research exploring Ricilina, evaluated in numerous Randomized Controlled Trials (RCTs) and comparative studies, was conducted to evaluate Ricilina for use in conditions such as Community-Acquired Pneumonia (CAP), Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), and Skin and Soft-Tissue Infections (SSTIs). These studies were used in research exploring how symptoms change over time in patients with these conditions. For pneumonia, studies were conducted during periods of increased symptom activity and focused on outcomes related to systemic or functional imbalance, such as tracking all-cause mortality, the need for hospitalization, and measurements of microbiological eradication. For exacerbations of bronchitis, research monitored physiological strain or stress and examined both the rate of subsequent flare-ups and the time interval between subsequent exacerbation episodes.

Studies monitored outcomes related to physical discomfort and systemic or functional imbalance. Findings helped contextualize how symptoms evolved in the observed populations. These studies were often evaluated against other antibiotics. The research highlights changes measured during the short study period, focusing primarily on clinical status and the resolution of key symptoms like fever and cough. The evidence contributes to the broader evidence landscape by providing context on short-term responses to treatment.

Evidence for Use in Middle Ear Infections and STIs

Ricilina was evaluated in large, comparative pediatric RCTs for Middle Ear Infection (Otitis Media) in children, focusing on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. For certain Sexually Transmitted Infections (STIs), research focused primarily on single-dose regimen trials, used in studies examining symptom intensity or variability. These trials tracked outcomes like microbiological cure (pathogen eradication) and the resolution of localized symptoms.

Long-Term Research and Follow-up Durations

The research base for Ricilina is largely comprised of studies observing responses over defined time intervals, meaning that typical follow-up durations were limited. For most acute infections, clinical assessment often occurred in the intermediate-term, such as at 10 to 30 days after the treatment course ended. While some studies, particularly those exploring long-term use in Chronic Bronchitis, were observed over longer periods (e.g., 6–12 months), the evidence for long-term patient-reported outcomes and the persistence of changes for the majority of acute conditions is not fully established. Research focuses predominantly on the initial response, and data are still emerging regarding effects that may occur months or years later.

Unanswered Questions and Research Gaps

Despite the significant body of research, the evidence highlights what is known and what is still uncertain about Ricilina. One critical limitation is the variability in findings that may be caused by heterogeneity across different study designs. The primary challenge acknowledged in the scientific literature is the ongoing evolution of antimicrobial resistance, which necessitates continuous research to ensure that the drug remains a relevant option for the bacterial infections for which it was studied.

Key Studies & References Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections

Frequently Asked Questions (FAQ)

Common questions about Ricilina (FAQ)


Q: How long does one dose of Ricilina stay active in the body?

A: Official pharmacokinetic data indicates that the active ingredient, Azithromycin, has a terminal elimination half-life of approximately 68 hours. This prolonged presence of the active ingredient in the body is a characteristic feature of this medication's profile.


Q: Can Ricilina be taken long-term?

A: Regulatory documents state that Ricilina is officially indicated for short-term courses of therapy to treat specific bacterial infections. The official prescribing information emphasizes that the medicine should only be used when there is a confirmed or highly suspected infection caused by susceptible bacteria.


Q: Is Ricilina a controlled substance?

A: Official regulatory documents and scheduling information confirm that Ricilina (Azithromycin) is not currently listed under the DEA Schedule of Controlled Substances. It is classified as a macrolide antibiotic.


Q: Is Ricilina available as a generic?

A: Yes, Ricilina's active ingredient is Azithromycin. Azithromycin is widely available in generic forms, which are required by regulatory agencies to meet the same strict quality and effectiveness standards as the brand-name drug.


Q: Is it normal to feel a change in appetite when starting Ricilina?

A: Changes in appetite, including a temporary loss of appetite, have been reported in clinical trials and post-marketing experience with Ricilina. Such effects are generally considered mild and temporary.


Q: Will Ricilina still work if I miss a dose?

A: Official patient information states that if a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the information states that the missed dose should be skipped. Two doses should never be taken together to make up for a missed one.


Q: Can older adults safely use Ricilina?

A: Official prescribing information notes that elderly patients may be more susceptible to serious heart rhythm abnormalities (like Torsades de pointes). Caution and professional monitoring are emphasized when Ricilina is used in the elderly population.


Q: What happens if I stop taking Ricilina suddenly?

A: Regulatory patient information stresses the importance of completing the full course of treatment as prescribed, even if symptoms begin to improve. Stopping the medicine too early may result in the original infection returning.


Q: Does Ricilina interact with alcohol?

A: While a direct harmful chemical interaction is not explicitly listed, official regulatory guidance generally describes that both the medication and alcohol may place a burden on the liver. They may also potentially amplify common side effects like dizziness or nausea.


Q: Is it possible to become dependent on Ricilina?

A: No, official regulatory classifications confirm that Ricilina (Azithromycin) is a macrolide antibiotic and is not associated with physical dependence or abuse potential.


Q: Does Ricilina affect fertility?

A: Official regulatory documentation indicates that there is no clear evidence described to suggest that taking Azithromycin reduces fertility in either men or women. However, for specific concerns regarding fertility, official guidance suggests discussing these with a healthcare professional.


Q: Can I take Ricilina with common pain relievers like ibuprofen?

A: Official interaction guidelines list specific drug categories but do not typically list common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as a major contraindication. The label always advises that all products, including pain relievers, should be reviewed with a healthcare professional.


Q: Why is Ricilina only available by prescription?

A: As a systemic antibacterial agent, Ricilina is classified as a prescription-only medicine because its use requires the accurate diagnosis of a bacterial infection. Professional oversight is noted as essential for accurate diagnosis and to help mitigate risks related to antimicrobial resistance.


Q: Can Ricilina affect my driving ability?

A: Regulatory documents list potential nervous system side effects such as dizziness or vertigo. Official patient information advises that if these effects occur, activities that require high mental alertness, such as driving or operating machinery, should be avoided.


Q: Are generic versions of Ricilina as effective as the brand name?

A: Yes, official regulatory agencies, including the FDA and others, classify generic medicines like Azithromycin as therapeutically equivalent to the brand-name version. This means they are required to have the same active ingredient, strength, quality, and intended clinical effect.


Q: What is the purpose of the black box warning on Ricilina?

A: Ricilina does not carry an official Black Box Warning from regulatory authorities. However, the official Warnings and Precautions section highlights serious, though rare, safety risks, including the potential for cardiovascular events and severe liver problems.


Q: How is Ricilina eliminated from the body?

A: Pharmacokinetic data indicates that Ricilina is primarily processed by the liver and then eliminated from the body via biliary excretion (through the bile and feces). Only a small portion of the unchanged drug is passed through the urine.


Q: Is Ricilina used for pain management?

A: No, official regulatory indications clearly classify Ricilina as an antibacterial drug intended only for the treatment of infections caused by susceptible bacteria. It is not indicated or used for the treatment of pain.


Q: Do I need to avoid certain activities while taking Ricilina?

A: Official guidance notes that due to the potential for side effects like dizziness or vision changes, activities requiring full alertness should be avoided if those effects occur. This includes driving or operating heavy machinery.


Q: Is Ricilina considered a novel treatment?

A: Ricilina’s active ingredient, Azithromycin, was initially approved in the U.S. in the early 1990s. It is classified as a semi-synthetic azalide (a subclass of macrolide antibiotics), meaning it is not considered a new or novel drug in the market.


Q: Is Ricilina safe to take with my daily vitamins?

A: The official label notes that a comprehensive review of all prescription and non-prescription products, including vitamins and herbal supplements, is necessary before starting Ricilina. The label does not list general vitamins as a major interaction.


Q: Are there specific symptoms that mean Ricilina is working?

A: Research studies tracked outcomes such as clinical cure and microbiological eradication, with success often being described by the resolution of key symptoms like fever and cough.


Q: What is the shelf life of Ricilina?

A: The shelf life for tablets or capsules is determined by the expiration date printed on the original package. For the oral suspension after it has been mixed, official patient information states it is typically stable for a maximum of 10 days when stored at the correct temperature.

How should Ricilina be stored and disposed of?

The storage and disposal of Ricilina (Azithromycin) must adhere to official regulatory conditions to maintain product stability and safety. The specific requirements vary by formulation.

Storage Conditions

Formulation Required Condition
Tablets Store below 30 C (controlled room temperature) in the original container.
Oral Suspension Store below 30 C; Do not freeze after reconstitution.

Stability and Safety

The reconstituted oral suspension is stable for a maximum of 10 days and must be discarded afterward. All forms must be kept out of the sight and reach of children for safety.

Disposal

Unused or expired Ricilina should be taken to a drug take-back program or disposed of according to local pharmaceutical waste regulations. The medicine must not be disposed of via wastewater (i.e., not flushed down the toilet or poured down the sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ricilina found in:

A-Z Index: